Special Issue "Viral Hepatitis Treatment"
Deadline for manuscript submissions: 15 December 2021.
Interests: chronic hepatitis; liver cirrhosis; autoimmune liver diseases; epatocellular carcinoma; liver transplantation; hepatic stem cells; metabolic liver diseases
The last 30 years have represented a continuous evolution of therapies in the management of viral liver infections that have a chronic course, in particular hepatitis B and C.
At the present time, recovery for those suffering from hepatitis C is practically universal. For those suffering from hepatitis B, in addition to a more refined diagnostic evaluation, several drugs with different therapeutic targets are being studied with the aim of a definitive cure. Moreover, for delta hepatitis, we are finally on the road to being able to achieve the same goals as hepatitis B through the development of drugs that block viral replication with the hope that they can also be effective for a definitive recovery.
Finally, in the recent COVID-19 pandemic, infection occurs in the liver, which appears to be one of the target organs of the virus, and we still do not know the possible outcomes of this.
This Special Issue of the Viruses journal is dedicated to the diagnostic and therapeutic advancements of viral liver diseases with the aim of giving a complete update not only on the treatments currently available and future developments, but also on the still unmet needs in the management of special patient populations.
Prof. Dr. Pietro Andreone
Prof. Dr. Stefano Brillanti
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- hepatitis A
- hepatitis B
- hepatitis C
- hepatitis delta
- hepatitis E
- COVID-19 hepatitis
- antiviral treatment
- viral hepatitis diagnosis